Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 15.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,704 shares of the biopharmaceutical company's stock after selling 1,821 shares during the period. Y Intercept Hong Kong Ltd's holdings in Regeneron Pharmaceuticals were worth $6,155,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. TD Private Client Wealth LLC raised its stake in shares of Regeneron Pharmaceuticals by 9.6% during the fourth quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock valued at $122,000 after acquiring an additional 15 shares during the last quarter. Adirondack Trust Co. grew its holdings in shares of Regeneron Pharmaceuticals by 4.2% during the first quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock valued at $286,000 after buying an additional 18 shares during the last quarter. Prestige Wealth Management Group LLC boosted its holdings in Regeneron Pharmaceuticals by 23.2% during the fourth quarter. Prestige Wealth Management Group LLC now owns 101 shares of the biopharmaceutical company's stock worth $72,000 after purchasing an additional 19 shares during the last quarter. Kingswood Wealth Advisors LLC boosted its holdings in Regeneron Pharmaceuticals by 1.8% during the first quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock worth $681,000 after purchasing an additional 19 shares during the last quarter. Finally, Creative Financial Designs Inc. ADV boosted its holdings in Regeneron Pharmaceuticals by 9.5% during the first quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company's stock worth $139,000 after purchasing an additional 19 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock traded down $1.85 during trading hours on Friday, hitting $562.79. The stock had a trading volume of 238,609 shares, compared to its average volume of 1,120,221. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.93 and a quick ratio of 4.03. The stock has a market capitalization of $60.76 billion, a price-to-earnings ratio of 14.32, a PEG ratio of 2.14 and a beta of 0.33. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,211.20. The stock's fifty day moving average is $543.18 and its two-hundred day moving average is $610.72.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The firm had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. During the same quarter last year, the business earned $9.55 earnings per share. The business's revenue for the quarter was down 3.7% compared to the same quarter last year. As a group, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.63%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.96%.

Wall Street Analyst Weigh In

Several brokerages have commented on REGN. Cantor Fitzgerald initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 price objective on the stock. JPMorgan Chase & Co. decreased their target price on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a report on Monday, June 9th. Citigroup decreased their target price on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating on the stock in a report on Monday, June 2nd. Robert W. Baird lowered their price objective on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research report on Friday, April 25th. Finally, Canaccord Genuity Group reissued a "buy" rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $837.61.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.